May 30, 2025

Hansa Biopharma welcomes Dr. Hitto Kaufmann as Chief Scientific Officer

Hansa Biopharma welcomes Dr. Hitto Kaufmann - Representative Image - Image by yanalya on Freepik
Hansa Biopharma welcomes Dr. Hitto Kaufmann - Representative Image - Image by yanalya on Freepik

Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced recently that Dr. Hitto Kaufmann has been appointed as Hansa’s Chief Scientific Officer (CSO) effective 1 December 2023.

As CSO, Dr. Kaufmann will be responsible for all research, early development, translational and manufacturing activities. He will report to President & Chief Executive Officer Søren Tulstrup and serve as a member of Hansa’s Executive Committee.

Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019. He led the company’s R&D platform developing innovative next generation protein therapeutics leading to regulatory submissions across several indications. He played an integral role in transforming the company’s operational excellence including accelerated development paths, machine-learning driven R&D and reliable high-performance manufacturing as well as delivery.

The CEO on the new appointment

Søren Tulstrup, President and CEO, Hansa Biopharma said, “We are thrilled to welcome Hitto to Hansa at this pivotal time. With over 20 years’ experience in research, development, and advancement of science, he is poised to lead the development of our scientific platform and advancement of our pipeline of exciting drug candidates for rare immunologic diseases and conditions. Hitto has a proven track record of developing innovative medicines, advancing strategic R&D partnerships, and building next generation therapeutic platforms. He has previously demonstrated an ability to build and lead high-performing teams in both large pharma and small biotech organizations.”

The new appointee on the new development

Hitto Kaufmann said: “I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. Hansa has cutting-edge science – specifically its unique versatile IgG antibody cleaving enzyme platform – that will help deliver better patient outcomes in areas of high unmet need. I look forward to joining a team of diverse, talented people and to working across the company to develop and deliver lifesaving and life-altering medicines.”

Source

For more news from the healthcare industry:

Astellas Acquires Iveric Bio

CULT Food Science to utilise Alcheme Bio’s flavour optimisation tech via partnership

Biosyngen opens new cell therapy GMP facility in Singapore

(Visited 76 times, 1 visits today)

Share:

Facebook
Twitter
WhatsApp
LinkedIn

 

Comments are closed.

Social Media

Most Popular

YASH Technologies Achieves the AWS Generative AI Competency
YASH Technologies Achieves the AWS Generative AI Competency
Books-A-Million's 24th Coffee for the Troops Campaign Surpasses 80,000 Bags Donated 22
Books-A-Million's 24th Coffee for the Troops Campaign Surpasses 80,000 Bags Donated
UNice Partners with Student Beans and Beans iD to Offer Exclusive Discounts
UNice Partners with Student Beans and Beans iD to Offer Exclusive Discounts for Students, Graduates, and Key Workers
SignaPay Opens New 15,000-Square-Foot Headquarters in Irving, Texas
SignaPay Opens New 15,000-Square-Foot Headquarters in Irving, Texas

Related Posts